Natera’s Fetal Focus™ sgNIPT Trial Data Earns Top Spot at SMFM Meeting — Natera, Inc.

Event summary

Natera’s EXPAND clinical trial for its Fetal Focus™ Single Gene NIPT (sgNIPT) selected for oral plenary presentation at the SMFM meeting, February 8-13, 2026.
EXPAND is a prospective, blinded trial validating Fetal Focus’ ability to detect inherited disease-causing variants in 21 genes using LinkedSNP™ technology.
Presentation will detail key results and robust study design, including confirmation against genetic truth.
Natera also presenting data from VANISH trial on Panorama™ NIPT for vanishing twin pregnancies.

The big picture

Natera’s selection for a plenary session at SMFM underscores the growing importance of non-invasive prenatal genetic testing in maternal-fetal medicine. The company is positioning itself as a leader in precision medicine, particularly in detecting serious early-onset conditions through cell-free DNA analysis. This strategic focus aligns with broader industry trends toward earlier, more targeted interventions in women’s health.

What we're watching

Clinical Validation Impact: How the EXPAND trial results will affect adoption of Fetal Focus™ in prenatal care.
Competitive Positioning: Whether Natera can leverage this data to strengthen its market position in non-invasive prenatal testing.
Regulatory Pathway: The pace at which positive trial results could accelerate regulatory approvals for expanded use cases.